UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/589,924	08/18/2006	Franz Xaver Schwarz	33660-US-PCT	1065
84983 7590 11/25/2009 SandozAG (Austria)- LUEDEKA, NEELY & GRAHAM, P.C.			EXAMINER	
P.O.BOX 1871 Knoxville, TN 37901		AHMED, HASAN SYED		
			ART UNIT	PAPER NUMBER
			1615	
			MAIL DATE	DELIVERY MODE
			11/25/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/589,924	SCHWARZ, FRANZ XAVER			
Office Action Summary	Examiner	Art Unit			
	HASAN S. AHMED	1615			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period wall. Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
 1) Responsive to communication(s) filed on <u>04 Seconds</u> 2a) This action is FINAL. 2b) This 3) Since this application is in condition for alloward closed in accordance with the practice under Expensive to communication(s) filed on <u>04 Seconds</u> 	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
 4) Claim(s) 1-10,14-26 and 32-34 is/are pending if 4a) Of the above claim(s) 14-26 and 32-34 is/are 5) Claim(s) is/are allowed. 6) Claim(s) 1-10 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or 	re withdrawn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the conference of the second seco	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>8/18/06</u>. 	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ùte			

Application/Control Number: 10/589,924

Art Unit: 1615

DETAILED ACTION

Page 2

Receipt is acknowledged of applicant's: (a) response to restriction requirement and amendment, filed on 4 September 2009; and (b) transmittal letter, statement under 37 CFR 3.73(b), and PTO/SB/81, all filed on 9 September 2009.

* * * * *

Election/Restrictions

Applicant's election with traverse of Group I in the reply filed on 4 September 2009 is acknowledged. The traversal is on the ground that a serious burden does not exist in examining all of the claims together. This is not found persuasive because elements exist in each of the groups which require searches in areas not required for the other groups.

The requirement is still deemed proper and is therefore made FINAL.

Claims 14-26 and 32-34 (as numbered in the amendment filed on 4 September 2009) are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 4 September 2009.

* * * * *

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

* * * * *

Art Unit: 1615

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3 and 5-10 are rejected under 35 U.S.C. 102(b) as being anticipated by EP 0 080 862 ("Grimmett") (cited in the IDS filed on 18 August 2006).

Grimmett discloses water-dispersible extruded granules comprising amoxicillin trihydrate and sugar (see e.g. page 1, line 14; claim 1). The granules are prepared by, "...bringing into association the components [of the granule] and thereafter extruding the blended mixture." See page 3, lines 2-6. The amoxicillin trihydrate and sugar, *inter alia*, are passed through a screen then extruded with an aqueous solution (dichloromethane) (reading on example 1) (see example 1). The extruded product is collected and passed through a screen and dried (reading on example 1) (see example 1). The dried extrudate is then blended with 5% SYLOID (reading on the homogenization of claim 1(e)) (see example 1). The granulate may be dissolved in water to form a syrup (reading on the suspension of claim 1(f)) (see page 3, lines 18-19). Sugar is the common word for sucrose, as such, the sugar disclosed by Grimmett is deemed to be functionally equivalent to the sucrose of instant claims 2, 3, and 8. Amoxycillin trihydrate concentration is disclosed as, e.g., 13.65% (reading on the ranges recited in instant claims 5-7) (see example 1). Sugar (sucrose) concentration is disclosed as,

Art Unit: 1615

e.g., 68.9% (see example 1). The granulate particle size is disclosed as 1000

micrometers (see example 1) (reading on claims 9 and 10).

* * * * *

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1 and 4 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 080 862 ("Grimmett") in view of U.S. 2002/0006433 ("Davidson") (cited in the IDS filed on 18 August 2006).

Grimmett is discussed above. Grimmett explains that the disclosed composition is beneficial the treatment of bacterial infections (see page 1, line 3). Grimmett differs from the instant application in that it does not teach the sugar alcohol of instant claim 4. However, granulate compositions comprising amoxicillin trihydrate and mannitol were known in the art at the time the instant application was filed, as evinced by Davidson (see, e.g., p. [0021]). Davidson explains that mannitol is beneficial as a chewable base (see, e.g., p. [0006]).

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to disclose a method of making a granulate comprising amoxicillin trihydrate and mannitol, as taught by Grimmett in view of Davidson. One of ordinary skill in the art at the time the invention was made would have been motivated to use

Application/Control Number: 10/589,924 Page 5

Art Unit: 1615

mannitol because it is beneficial as a chewable base, as explained by Davidson (see above).

*

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to HASAN S. AHMED whose telephone number is (571)272-4792. The examiner can normally be reached on 9am - 5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571)272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/H. S. A./ Examiner, Art Unit 1615

/Humera N. Sheikh/
Primary Examiner, Art Unit 1615